IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES TAKEDA
Company/Organization Date Area of
Collaboration
Terms of Agreement
Lexicon Genetics 2004 Hypertension Lexicon will receive an upfront payment of
$12 million from Takeda for the initial
three-year term of the agreement. Takeda
has the option to extend the discovery
portion of the alliance for an additional two
years in exchange for further committed
funding. Takeda will make milestone
payments for each target selected for
development, while Lexicon will earn
royalties on worldwide sales of
commercialized drugs. $5m research
milestone payment paid in 2006 when
Takeda selected LG 474 for therapeutic
development.
Evotec 2003 Alzheimer’s disease Evotec and Takeda agreed a four year
collaboration to identify and validate
targets relating to the causes and
progression of AD. Takeda will gain access
to Evotec’s database of targets, and use
Evotec’s expertise to further validate
selected targets. Takeda will pay a Euro20
million fee for access, research funding
and milestone payments. Further
milestone payments may become payable
on successful clinical development. A
second milestone was due in 2006.
Kirin Brewery 2003 Cancer therapy Takeda in-licensed Kirin’s TransChromo
Mouse technology to produce fully
humanized MAbs against selected target
protein antigens. Takeda will develop,
manufacture and market any resulting
products worldwide, in return for
development milestone and sales royalty
payments. No financial details were
announced. Takeda confirmed ongoing in
2008.
Beth Israel Deaconess
Medical Center
2003 Diabetes and obesity BIDMC and Takeda signed a 3 year
agreement worth $13.7m to investigate
the molecular basis of diabetes and
obesity. Takeda will have an exclusive
option to negotiate a license to intellectual
property derived from the collaboration
and BIDMC will gain access to Takeda’s
R&D expertise in the field.
© 2009 IMS Health In cor po rated or its af fil i ates Page 103